This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Category: Uncategorized
-
Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm®
•
(Little Falls, NJ) – November 1, 2016 – Regenicin, Inc., a biotechnology company a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that they have completed the Pre-IND (Investigational New Drug) Meeting via teleconference with…